These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1132 related articles for article (PubMed ID: 24259638)

  • 1. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD).
    Sharma A; Couture J
    Ann Pharmacother; 2014 Feb; 48(2):209-25. PubMed ID: 24259638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attention deficit hyperactivity disorder in adults.
    Rösler M; Casas M; Konofal E; Buitelaar J
    World J Biol Psychiatry; 2010 Aug; 11(5):684-98. PubMed ID: 20521876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL
    Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
    Eiland LS; Bell EA; Erramouspe J
    Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and Investigational Medication Delivery Systems for Treating Attention-Deficit/Hyperactivity Disorder.
    Jain R; Katic A
    Prim Care Companion CNS Disord; 2016 Aug; 18(4):. PubMed ID: 27828696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurofunctional effects of methylphenidate and atomoxetine in boys with attention-deficit/hyperactivity disorder during time discrimination.
    Smith A; Cubillo A; Barrett N; Giampietro V; Simmons A; Brammer M; Rubia K
    Biol Psychiatry; 2013 Oct; 74(8):615-22. PubMed ID: 23731741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prescribing ritalin in combined modality management of hyperactivity with attention deficit].
    Bricard C; Boidein F
    Encephale; 2001; 27(5):435-43. PubMed ID: 11760693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
    Gibson AP; Bettinger TL; Patel NC; Crismon ML
    Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological management of attention-deficit hyperactivity disorder.
    Reeves G; Schweitzer J
    Expert Opin Pharmacother; 2004 Jun; 5(6):1313-20. PubMed ID: 15163276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current pharmacotherapy of attention deficit hyperactivity disorder.
    Reddy DS
    Drugs Today (Barc); 2013 Oct; 49(10):647-65. PubMed ID: 24191257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic, toxicological, and safety considerations for drugs used to treat ADHD.
    Duong S; Chung K; Wigal SB
    Expert Opin Drug Metab Toxicol; 2012 May; 8(5):543-52. PubMed ID: 22413882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Attention Deficit Hyperactivity Disorder (ADHD) and road traffic - special considerations for the treatment of adolescents with ADHD].
    Ludolph AG; Kölch M; Plener PL; Schulze UM; Spröber N; Fegert JM
    Z Kinder Jugendpsychiatr Psychother; 2009 Sep; 37(5):405-11. PubMed ID: 19739058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
    Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
    Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychopharmacology of Attention-Deficit Hyperactivity Disorder: Effects and Side Effects.
    Golmirzaei J; Mahboobi H; Yazdanparast M; Mushtaq G; Kamal MA; Hamzei E
    Curr Pharm Des; 2016; 22(5):590-4. PubMed ID: 26601963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atomoxetine treatment of attention-deficit/hyperactivity disorder.
    Eiland LS; Guest AL
    Ann Pharmacother; 2004 Jan; 38(1):86-90. PubMed ID: 14742801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attention deficit hyperactivity disorder in the European adult population: prevalence, disease awareness, and treatment guidelines.
    Ramos-Quiroga JA; Montoya A; Kutzelnigg A; Deberdt W; Sobanski E
    Curr Med Res Opin; 2013 Sep; 29(9):1093-104. PubMed ID: 23742051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of pharmacotherapy options for the treatment of attention-deficit/hyperactivity disorder (ADHD) and ADHD-like symptoms in children and adolescents with developmental disorders.
    Rowles BM; Findling RL
    Dev Disabil Res Rev; 2010; 16(3):273-82. PubMed ID: 20981766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.